Xaluritamig contains two STEAP1-binding domains and a CD3-binding domain, enabling the recognition of both cancer cells and T cells and leading to efficient T-cell-mediated cytotoxicity against STEAP1-expressing cells [69]. This evidence concerns the gene STEAP1 and cancer.